South Korea
· Delayed Price · Currency is KRW Genesystem Statistics
Total Valuation
Genesystem has a market cap or net worth of KRW 71.10 billion. The enterprise value is 70.14 billion.
| Market Cap | 71.10B |
| Enterprise Value | 70.14B |
Important Dates
The next estimated earnings date is Thursday, June 19, 2025.
| Earnings Date | Jun 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genesystem has 7.03 million shares outstanding. The number of shares has decreased by -1.47% in one year.
| Current Share Class | 7.03M |
| Shares Outstanding | 7.03M |
| Shares Change (YoY) | -1.47% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 18.39% |
| Owned by Institutions (%) | 18.46% |
| Float | 5.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.87 |
| PB Ratio | 3.25 |
| P/TBV Ratio | 5.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.87 |
| EV / Sales | 58.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.23 |
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.19.
| Current Ratio | 3.93 |
| Quick Ratio | 3.08 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.54 |
| Interest Coverage | -74.25 |
Financial Efficiency
Return on equity (ROE) is -36.26% and return on invested capital (ROIC) is -20.67%.
| Return on Equity (ROE) | -36.26% |
| Return on Assets (ROA) | -18.37% |
| Return on Invested Capital (ROIC) | -20.67% |
| Return on Capital Employed (ROCE) | -36.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.04 |
| Inventory Turnover | 1.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.81% in the last 52 weeks. The beta is 0.60, so Genesystem's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +68.81% |
| 50-Day Moving Average | 10,366.40 |
| 200-Day Moving Average | 9,962.45 |
| Relative Strength Index (RSI) | 45.23 |
| Average Volume (20 Days) | 39,847 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genesystem had revenue of KRW 1.21 billion and -8.92 billion in losses. Loss per share was -1,302.00.
| Revenue | 1.21B |
| Gross Profit | -1.82B |
| Operating Income | -10.12B |
| Pretax Income | -9.68B |
| Net Income | -8.92B |
| EBITDA | -8.87B |
| EBIT | -10.12B |
| Loss Per Share | -1,302.00 |
Balance Sheet
The company has 7.69 billion in cash and 4.12 billion in debt, giving a net cash position of 3.57 billion or 508.15 per share.
| Cash & Cash Equivalents | 7.69B |
| Total Debt | 4.12B |
| Net Cash | 3.57B |
| Net Cash Per Share | 508.15 |
| Equity (Book Value) | 21.88B |
| Book Value Per Share | 2,833.77 |
| Working Capital | 7.44B |
Cash Flow
In the last 12 months, operating cash flow was -7.34 billion and capital expenditures -258.73 million, giving a free cash flow of -7.60 billion.
| Operating Cash Flow | -7.34B |
| Capital Expenditures | -258.73M |
| Free Cash Flow | -7.60B |
| FCF Per Share | -1,080.01 |
Margins
| Gross Margin | -150.68% |
| Operating Margin | -837.58% |
| Pretax Margin | -801.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genesystem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.47% |
| Shareholder Yield | 1.47% |
| Earnings Yield | -12.54% |
| FCF Yield | -10.68% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genesystem has an Altman Z-Score of 3.83.
| Altman Z-Score | 3.83 |
| Piotroski F-Score | n/a |